Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01905592 · ClinicalTrials.gov registry record · Phase 3
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase 3 study, sponsored by Tesaro.
- Terminated
- Registry status
- Phase 3
- Development phase
- 216
- Enrollment target
NCT01905592 is a Phase 3 study that was terminated before completion, run by Tesaro. The registered enrollment target is 216 participants.
The verdict
NCT01905592, a Phase 3 study, was terminated before completion, sponsored by Tesaro.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 216 participants
- Enrollment target
Study Summary
The purpose of this study is to compare progression-free survival (PFS) in patients with advanced/metastatic breast cancer who have a BRCA mutation when treated with niraparib as compared to those treated with physician's choice
Interventions
- DRUG Physician's choice
- DRUG niraparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2014-02-25 |
| Est. Completion | 2021-10-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01905592
The ClinicalTrials.gov registry entry for NCT01905592 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tesaro, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Physician's choice is the first listed.
NCT01905592 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01905592 about?
NCT01905592 is a clinical study titled "A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients". The purpose of this study is to compare progression-free survival (PFS) in patients with advanced/metastatic breast cancer who have a BRCA mutation when treated with niraparib as compared to those treated with physician's choice
What is the current status of trial NCT01905592?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 216 participants. The study started on 2014-02-25. Estimated completion is 2021-10-26.
What interventions are being tested in trial NCT01905592?
The interventions under investigation include: Physician's choice (DRUG), niraparib (DRUG).
Who is sponsoring clinical trial NCT01905592?
This trial is sponsored by Tesaro, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.